Ticker: CERO

CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) - Quick reality check What's happening inside: management is advancing clinical work (CER‑1236 IND active, first AML patient dosed with no dose‑limiting toxicity), but the company is burning cash, relying on frequent financings and facing governance...